|Other Names||NEDD8 ultimate buster 1, Negative regulator of ubiquitin-like proteins 1, Renal carcinoma antigen NY-REN-18, NUB1, NYREN18|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP2510b was selected from the C-term region of human NYREN18 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Specific down-regulator of the NEDD8 conjugation system. Recruits NEDD8, UBD, and their conjugates to the proteasome for degradation. Isoform 1 promotes the degradation of NEDD8 more efficiently than isoform 2.|
|Cellular Location||Nucleus. Note=Predominantly nuclear|
|Tissue Location||Widely expressed with lowest expression in the pancreas for isoform 1 and in leukocytes, liver, prostate and skeletal muscle for isoform 2|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
NYREN18 is a specific down-regulator of the NEDD8 conjugation system. It recruits NEDD8 and its conjugates to the proteasome for degradation. It also interacts with PSMD4/S5a, a member of the regulatory subunit of the 26S proteasome.
Tanaka, T., et al., J. Biol. Chem. 278(35):32905-32913 (2003).Akey, D.T., et al., Hum. Mol. Genet. 11(22):2723-2733 (2002).Kito, K., et al., J. Biol. Chem. 276(23):20603-20609 (2001).Scanlan, M.J., et al., Int. J. Cancer 83(4):456-464 (1999).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.